-
Mashup Score: 7‘Patient Is Otherwise Healthy’ - 1 month(s) ago
Let me start by saying: I know I am one of the fortunate ones. Being diagnosed with cancer at any age puts many in a tailspin. I was no different when I was diagnosed with stage II testicular cancer at age 22 years. I was still in graduate school, completing my physical therapy program; suddenly, I had to schedule an orchiectomy, retroperitoneal lymph node dissection, and two cycles of chemotherapy around lectures, laboratory work, and practical examinations. Fast forward 20 years and I have an unbelievabl
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Northwell Cancer Institute names system chief of blood and marrow transplant and cellular therapy - 1 month(s) ago
As system chief, A. Samer Al-Homsi, MD, MBA, will oversee the growth of the Cancer Institute’s existing Blood and Marrow Transplant Program, among other responsibilities.
Source: www.northwell.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
Is “quiet quitting” about being lazy or setting healthy boundaries? Is it even real? We dig into the data and ask workers themselves about what it means to them.
Source: www.npr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Has quiet quitting hurt healthcare leadership? 4 execs weigh in - 2 month(s) ago
“Discover the impact of “quiet quitting” and disengagement on healthcare talent development and succession planning, as industry leaders share insights on promo
Source: www.beckershospitalreview.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 193
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival (OS). We evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study. METHODS We performed targeted sequencing in 309 patients age 50-75 years with International Prognostic Scoring System (IPSS) intermediate-2 or high-risk MDS, enrolled in the Blood and Marrow Transplant Clinical Trials Network 1102 study and assessed the association of gene mutations with OS. Patients with TP53 mutations were classified as TP53multihit if two alleles were altered (via point mutation, deletion, or copy-neutral loss of heterozygosity). RESULTS The distribution of gene mutations was similar in the donor and no donor arms, with TP53 (28% v 29%; P = .89), ASXL1 (23% v 29%; P = .37), and SRSF2 (16% v 16%; P = .99) being most common. OS in patients with a TP53 mutation was worse compared with patients without TP53 mutation (21
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 186
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival (OS). We evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study. METHODS We performed targeted sequencing in 309 patients age 50-75 years with International Prognostic Scoring System (IPSS) intermediate-2 or high-risk MDS, enrolled in the Blood and Marrow Transplant Clinical Trials Network 1102 study and assessed the association of gene mutations with OS. Patients with TP53 mutations were classified as TP53multihit if two alleles were altered (via point mutation, deletion, or copy-neutral loss of heterozygosity). RESULTS The distribution of gene mutations was similar in the donor and no donor arms, with TP53 (28% v 29%; P = .89), ASXL1 (23% v 29%; P = .37), and SRSF2 (16% v 16%; P = .99) being most common. OS in patients with a TP53 mutation was worse compared with patients without TP53 mutation (21
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country - 2 month(s) ago
PURPOSE Myelodysplastic syndromes (MDS) include a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis. They manifest as dysplasia in bone marrow hemopoietic elements associated with peripheral cytopenias with variable risk of AML transformation. PATIENTS AND METHODS We analyzed retrospectively registry data collected prospectively from patients with primary MDS and patients with MDS/myeloproliferative neoplasm (MPN) in the Jordan University Hospital between January 2007 and September 2021. The registry captured epidemiologic information such as date of diagnosis, age, gender, date of AML transformation, cytogenetics, MDS subtype, risk group according to Revised International Prognostic Scoring System, and survival. The registry also captured baseline ferritin, B12, and lactate dehydrogenase levels. RESULTS A total of 112 patients with MDS and MDS/MPN were included in the registry. Median age at diagnosis was 59 years. The male-to-female ratio
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Need help making sense of the rapidly changing diagnosis and treatment standards in higher-risk myelodysplastic syndrome (HR-MDS)?
Source: www.medscape.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29
Edited by Associate Editor Thomas Ortel, this How I Treat series on hematologic complications of pregnancy uses illustrative cases to discuss the management of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29
Edited by Associate Editor Thomas Ortel, this How I Treat series on hematologic complications of pregnancy uses illustrative cases to discuss the management of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
RT @ElizabethPrsic: ‘Patient Is Otherwise Healthy’ | JCO Oncology Practice https://t.co/nDVbMrxHDI Wonderful work from our @SmilowCancer…